8-K - Arrowhead Pharmaceuticals, Inc. | StockGist

Current Report Details

Event Type

Regulation Fd

Other Event

Exhibits Only

Disclosure

Voluntary

Variant

8-K

Items Reported

7.01

of this Current Report on Form 8-K, including the information in the press release and the presentation attached as Exhibit 99.1 and Exhibit 99.2, respectively,

Regulation Fd

8.01

Other Events. On January 6, 2026, the Company announced interim results from its Phase 1/2a clinical trials of ARO-INHBE and ARO-ALK7. Select ARO-INHBE Phase 1/

Other Event

9.01

. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated January 6, 2026 99.2 Presentation, dated January 6, 2026 104

Exhibits Only

Source Document

Exhibits (3)

8-K

99.1

EX-99.1

99.2

EX-99.2